Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation.
Carcinoma, Hepatocellular
/ immunology
Female
Humans
Liver Neoplasms
/ immunology
Liver Transplantation
Male
Mast Cells
/ pathology
Middle Aged
Neoplasm Recurrence, Local
/ immunology
Postoperative Period
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Treatment Outcome
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
10
05
2021
received:
01
03
2021
accepted:
23
05
2021
pubmed:
25
9
2021
medline:
28
1
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Tumor-infiltrating immune cells are relevant prognostic and immunotherapeutic targets in hepatocellular carcinoma (HCC). Mast cells play a key role in allergic response but may also be involved in anticancer immunity. Digital morphometric analysis of patient tissue sections has become increasingly available for clinical routine and provides unbiased quantitative data. Here, we apply morphometric analysis of mast cells to retrospectively evaluate their relevance for HCC recurrence in patients after orthotopic liver transplantation (OLT). A total of 173 patients underwent OLT for HCC at the Medical University of Vienna (21 women, 152 men; 55.2 ± 7.9 years; 74 beyond Milan criteria, 49 beyond up-to-7 criteria for liver transplantation). Tissue arrays from tumors and corresponding surrounding tissues were immunohistochemically stained for mast cell tryptase. Mast cells were quantified by digital tissue morphometric analysis and correlated with HCC recurrence. Mast cells were detected in 93% of HCC tumors and in all available surrounding liver tissues. Tumor tissues revealed lower mast cell density than corresponding surrounding tissues (P < 0.0001). Patients lacking intratumoral mast cells (iMCs) displayed larger tumors and higher tumor recurrence rates both in the whole cohort (hazard ratio [HR], 2.74; 95% confidence interval [CI], 1.09-6.93; P = 0.029) and in patients beyond transplant criteria (Milan HR, 2.81; 95% CI, 1.04-7.62; P = 0.01; up-to-7 HR, 3.58; 95% CI, 1.17-10.92; P = 0.02). Notably, high iMC identified additional patients at low risk classified outside the Milan and up-to-7 criteria, whereas low iMC identified additional patients at high risk classified within the alpha-fetoprotein French and Metroticket criteria. iMCs independently predicted tumor recurrence in a multivariate Cox regression analysis (Milan HR, 2.38; 95% CI, 1.16-4.91; P = 0.019; up-to-7 HR, 2.21; 95% CI, 1.05-4.62; P = 0.035). Conclusion: Hepatic mast cells might be implicated in antitumor immunity in HCC. Morphometric analysis of iMCs refines prognosis of HCC recurrence after liver transplantation.
Identifiants
pubmed: 34558826
doi: 10.1002/hep4.1770
pmc: PMC8557312
pii: 02009842-202111000-00013
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1939-1952Informations de copyright
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
El‐Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557‐2576.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69‐90. Erratum in: CA Cancer J Clin 2011;61:134.
Ramadori G, Moriconi F, Malik I, Dudas J. Physiology and pathophysiology of liver inflammation, damage and repair. J Physiol Pharmacol 2008;59(Suppl 1):107‐117.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245‐1255.
He G, Karin M. NF‐kappaB and STAT3 ‐ key players in liver inflammation and cancer. Cell Res 2011;21:159‐168.
Park EJ, Lee JH, Yu G‐Y, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL‐6 and TNF expression. Cell 2010;140:197‐208.
Pinter M, Peck‐Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598‐609.
Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408‐424. Erratum in: Nat Rev Clin Oncol 2015;12:436.
Kulik L, El‐Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477‐491.e471.
European Association for the Study of the Liver . EASL Clinical Practice Guidelines: liver transplantation. J Hepatol 2016;64:433‐485.
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394‐1403.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; Metroticket Investigator Study Group . Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35‐43.
Duvoux C, Roudot–Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al.; Liver Transplantation French Study Group . Liver transplantation for hepatocellular carcinoma: a model including α‐fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986‐994.e983.
Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128‐139.
Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg 2017;265:557‐564.
Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, et al. Is it time to abandon the Milan Criteria?: results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies. Ann Surg 2018;268:690‐699.
von Felden J, Villanueva A. Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma. Liver Transpl 2020;26:823‐831.
Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying baseline immune‐related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 2017;5:44.
Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016;44:698‐711.
Rohr‐Udilova N, Klinglmüller F, Schulte‐Hermann R, Stift J, Herac M, Salzmann M, et al. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep 2018;8:6220.
Cancer Genome Atlas Research Network . Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017;169:1327‐1341.e1323.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453‐457.
Crivellato E, Ribatti D. The mast cell: an evolutionary perspective. Biol Rev Camb Philos Soc 2010;85:347‐360.
Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. J Allergy Clin Immunol 2018;142:381‐393.
Maurer M, Wedemeyer J, Metz M, Piliponsky AM, Weller K, Chatterjea D, et al. Mast cells promote homeostasis by limiting endothelin‐1‐induced toxicity. Nature 2004;432:512‐516.
Kennedy Norton S, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, et al. IL‐10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 2008;180:2848‐2854.
Debruin E, Gold M, Lo B, Snyder K, Cait A, Lasic N, et al. Mast cells in human health and disease. Methods Mol Biol 2015;1220:93‐119.
Johnson C, Huynh V, Hargrove L, Kennedy L, Graf‐Eaton A, Owens J, et al. Inhibition of mast cell‐derived histamine decreases human cholangiocarcinoma growth and differentiation via c‐kit/stem cell factor‐dependent signaling. Am J Pathol 2016;186:123‐133.
Jones H, Hargrove L, Kennedy L, Meng F, Graf‐Eaton A, Owens J, et al. Inhibition of mast cell‐secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(‐/‐) mice. Hepatology 2016;64:1202‐1216.
Kennedy LL, Hargrove LA, Graf AB, Francis TC, Hodges KM, Nguyen QP, et al. Inhibition of mast cell‐derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents. Lab Invest 2014;94:1406‐1418.
Tu JF, Pan HY, Ying XH, Lou J, Ji JS, Zou H. Mast cells comprise the major of interleukin 17‐producing cells and predict a poor prognosis in hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e3220.
Ju MJ, Qiu SJ, Gao Q, Fan J, Cai MY, Li YW, et al. Combination of peritumoral mast cells and T‐regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci 2009;100:1267‐1274.
Lin SZ, Chen KJ, Xu ZY, Chen H, Zhou L, Xie HY, et al. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells. Cancer Prev Res (Phila) 2013;6:594‐602.
Wei L, Delin Z, Kefei Y, Hong W, Jiwei H, Yange Z. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. Oncoimmunology 2019;9:1672495.
Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness‐of‐fit tests for the logistic regression model. Stat Med 1997;16:965‐980.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646‐674.
Theret N, Musso O, Turlin B, Lotrian D, Bioulac‐Sage P, Campion JP, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001;34:82‐88.
Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, et al. Dynamic changes in PD‐L1 expression and immune infiltrates early during treatment predict response to PD‐1 blockade in melanoma. Clin Cancer Res 2017;23:5024‐5033.
Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD‐1 blockade expands intratumoral memory T cells. Cancer Immunol Res 2016;4:194‐203.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD‐1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568‐571.
Mehdawi L, Osman J, Topi G, Sjolander A. High tumor mast cell density is associated with longer survival of colon cancer patients. Acta Oncol 2016;55:1434‐1442.
Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005;11:1210‐1214.
Tomita M, Matsuzaki Y, Onitsuka T. Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma. Lung Cancer 1999;26:103‐108.
Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P, et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 2007;7:165.
Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Badjik C, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004;17:690‐695. Erratum in: Mod Pathol 2004;17:1025.
Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev 2018;282:121‐150.
Kennedy L, Hargrove L, Demieville J, Karstens W, Jones H, DeMorrow S, et al. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2(‐/‐) mice and human cholangiocarcinoma tumorigenesis. Hepatology 2018;68:1042‐1056.
Kyritsi K, Kennedy L, Meadows V, Hargrove L, Demieville J, Pham L, et al. Mast cells induce ductular reaction mimicking liver injury in mice through mast cell‐derived transforming growth factor beta 1 signaling. Hepatology 2021; 73: 2397‐2410. https://doi.org/10.1002/hep.31497 .
doi: 10.1002/hep.31497
Terada T, Matsunaga Y. Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol 2000;33:961‐966.
Oldford SA, Marshall JS. Mast cells as targets for immunotherapy of solid tumors. Mol Immunol 2015;63:113‐124.
Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, et al. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): a case report and literature review. Medicine (Baltimore) 2018;97:e12866.
Burke SM, Issekutz TB, Mohan K, Lee PW, Shmulevitz M, Marshall JS. Human mast cell activation with virus‐associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8‐dependent mechanism. Blood 2008;111:5467‐5476.
Sung PS, Jang JW. Natural killer cell dysfunction in hepatocellular carcinoma: pathogenesis and clinical implications. Int J Mol Sci 2018;19:3648.
Ghiara P, Boraschi D, Villa L, Scapigliati G, Taddei C, Tagliabue A. In vitro generated mast cells express natural cytotoxicity against tumour cells. Immunology 1985;55:317‐324.
Karovic S, Shiuan EF, Zhang SQ, Cao H, Maitland ML. Patient‐level adverse event patterns in a single‐institution study of the multi‐kinase inhibitor sorafenib. Clin Transl Sci 2016;9:260‐266.
Wang P, Tan G, Zhu M, Li W, Zhai B, Sun X. Hand‐foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta‐analysis. Expert Rev Gastroenterol Hepatol 2018;12:1‐8.
Díaz‐González Á, Sanduzzi‐Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, et al. Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2019;49:482‐491.
Mizukami Y, Sugawara K, Kira Y, Tsuruta D. Sorafenib stimulates human skin type mast cell degranulation and maturation. J Dermatol Sci 2017;88:308‐319.
Josephs DH, Spicer JF, Corrigan CJ, Gould HJ, Karagiannis SN. Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy 2013;43:1110‐1123.
Jensen‐Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, et al. AllergoOncology ‐ the impact of allergy in oncology: EAACI position paper. Allergy 2017;72:866‐887.
Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, et al. IgE/FcepsilonRI‐mediated antigen cross‐presentation by dendritic cells enhances anti‐tumor immune responses. Cell Rep 2015;10:1487‐1495.
Mehta N, Yao FY. What are the optimal liver transplantation criteria for hepatocellular carcinoma? Clin Liv Dis (Hoboken) 2019;13:20‐25.